Biomerieux (OTC:BMXXY) Stock, Quote.Headers.trade-ideas

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.

Press Releases

Global In Vitro Diagnostics Leader bioMérieux Celebrates the Opening of the Molecular and Genomic Innovation Center at the Navy Yard in Philadelphia

bioMérieux Launches GENE-UP® TYPER,an Innovative Diagnostic Solution for Food Industries to Rapidly Analyze the Root Causeof Contamination of Listeria monocytogenes

bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance

BMXXY

BIOMERIEUX S A UNSP/ADR by BIOMERIEUX S A

Comments

Biomerieux

Biomerieux (OTC:BMXXY) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell